Saudi orthopedic society guidelines for treating patients with bone and soft-tissue tumors during the COVID-19 pandemic

Abstract

The coronavirus disease 2019 (COVID-19) pandemic presented a significant challenge to health-care systems globally. The Saudi government took rapid and unprecedented precautionary measures to limit this disease's explosive spread. [1,2] Nevertheless, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) had infected almost 360,000 patients in Saudi Arabia by early December 2020. [3] This, in turn, jeopardized the ability of the health-care service to provide the required medical care for COVID-19 and non-COVID-19 patients. Cancer patients are more susceptible to infection than individuals without cancer because of the systemic immunosuppressive

The effect of COVID-19 on orthopedic elective/emergency procedures in a tertiary hospital Riyadh Saudi Arabia. A cross-sectional study

“…Trauma and oncology units did not have significant restrictions like other subspecialties and were operating as usual [ 4 , [6] , [7] , [8] ]. The oncology chapter of the Saudi orthopedic society issued guidelines that recommended not to delay treatment of any malignant osseous or soft tissue tumors and metastatic fracture or a lesion with impending pathological fracture [ 18 ]. In our study, oncology unit cases increased by 10.5% compared to 2nd Q 2019 and decreased by 38.2% from 1st Q 2020.…”